[go: up one dir, main page]

TN2014000371A1 - MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES - Google Patents

MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES

Info

Publication number
TN2014000371A1
TN2014000371A1 TNP2014000371A TN2014000371A TN2014000371A1 TN 2014000371 A1 TN2014000371 A1 TN 2014000371A1 TN P2014000371 A TNP2014000371 A TN P2014000371A TN 2014000371 A TN2014000371 A TN 2014000371A TN 2014000371 A1 TN2014000371 A1 TN 2014000371A1
Authority
TN
Tunisia
Prior art keywords
treatment
compounds
proliferative diseases
salts
macrocyclic derivatives
Prior art date
Application number
TNP2014000371A
Other languages
French (fr)
Inventor
John Charles Kath
Jingrong Jean Cui
Simon Bailey
Benjamin Joseph Burke
Michael Raymond Collins
Judith Gail Deal
Robert Louis Hoffman
Qinhua Huang
Ted William Johnson
Robert Steven Kania
Phuong Thi Quy Le
Michele Ann Mctigue
Cynthia Louise Palmer
Paul Francis Richardson
Neal William Sach
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2013/051391 external-priority patent/WO2013132376A1/en
Application filed by Pfizer filed Critical Pfizer
Publication of TN2014000371A1 publication Critical patent/TN2014000371A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule ( Φ) tels que définis plus en détail dans le présent mémoire et leurs sels sels pharmaceutiquement acceptables, des compositions pharmaceutiques comprenant ces composés et sels ainsi que leurs utilisations. Les composés et sels de la présente invention inhibent la kinase lymphome anaplasique (ALK) et/ou l'EML 4-ALK et sont utiles pour le traitement ou l'amelioration de troubles prolifératifs cellulaires, tels que le cancer.The present invention relates to compounds of formula (Φ) as further defined herein and their pharmaceutically acceptable salt salts, pharmaceutical compositions comprising such compounds and salts and uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and / or EML 4-ALK and are useful for the treatment or amelioration of cellular proliferative disorders, such as cancer.

TNP2014000371A 2013-01-31 2014-08-28 MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES TN2014000371A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361759307P 2013-01-31 2013-01-31
PCT/IB2013/051391 WO2013132376A1 (en) 2012-03-06 2013-02-20 Macrocyclic derivatives for the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
TN2014000371A1 true TN2014000371A1 (en) 2015-12-21

Family

ID=53365645

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2014000371A TN2014000371A1 (en) 2013-01-31 2014-08-28 MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES

Country Status (2)

Country Link
CU (1) CU20140107A7 (en)
TN (1) TN2014000371A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112321604A (en) * 2019-08-05 2021-02-05 华东理工大学 Macrocyclic JAK2 inhibitors and their applications
WO2024146541A1 (en) * 2023-01-03 2024-07-11 Guangdong Newopp Biopharmaceuticals Co., Ltd. Macrocyclic compounds as usp1 inhibitors

Also Published As

Publication number Publication date
CU20140107A7 (en) 2014-12-26

Similar Documents

Publication Publication Date Title
MA40111A1 (en) Derivatives of tetrahydronaphthalene inhibiting mcl-1 protein
MA40225A (en) SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS
MA45598B1 (en) 24-hydroxy steroles substituted in position 11 for the treatment of diseases linked to the nmda receptor
MA42410B1 (en) Oxysterols and their methods of use
MA38391A1 (en) Pyridinyl and triazolone pyridinyl derivatives of fusion
MA44674A (en) BROMODOMAIN INHIBITORS
MA47079B1 (en) Amino-triazolopyidin compounds and their use to treat cancer
TN2014000537A1 (en) 4- (AMINO-SUBSTITUTED) - NEW 7H-PYRROLO [2,3-D] PYRIMIDINES AS INHIBITORS OF LRRK2
WO2019035863A8 (en) Pyruvate kinase activators for use in treating blood disorders
MA39898B1 (en) 4-amino-imidazoquinoline compounds
MA39783B1 (en) Quinoxaline derivatives useful as modulators of fgfr kinase
MA38398B1 (en) Biaryl amide compounds as kinase inhibitors
MA53399B1 (en) Substituted pyrazoles as inhibitors of human plasma kallikrein
MA37400B1 (en) Heterocyclyl compounds as mek inhibitors
MA47356A1 (en) Isochromene derivatives useful as inhibitors of phosphoinositide 3-kinases
MA46229B1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
MA37831A1 (en) Azaindole derivatives acting as pi3k inhibitor
MA39165A1 (en) Benzimidazole-proline derivatives for their use in the treatment of crepuscular state syndrome
MA43052B1 (en) Human Plasma Kallikrein Inhibitors
MA33760B1 (en) Derivatives of spirulactamates and their use
MA40149A1 (en) Substituted 4'-vinyl nucleoside derivatives useful as inhibitors of respiratory syncytial virus rna replication
MA39186A1 (en) Derivatives of [1,2,4] triazolo [1,5-a] pyrimidine used as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
MA38250B1 (en) New hydantoin derivatives for their uses in the treatment of diseases, such as osteoporosis and thrombocytopenia
MA44965A (en) PYRIDINYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES OF THEM AS AOC3 INHIBITORS
TN2014000371A1 (en) MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES